This study used female Swiss mice aged 6 to 8 weeks weighing 17–23 g. They were acquired from the Central Animal Facility of the Federal University of Goiás and placed in the Laboratory of Biomolecules and Vaccines (LaBVac) pre-clinical testing room. The mice were housed in a pathogen-free primary enclosure with free access to food and water; the enclosure was maintained at 24 °C, with odor and light control with a light and dark cycle every 12 h. All animals in this experiment were previously dewormed with access to a 1:20 Ivermectin® solution for seven days. The experiments were conducted following ethical recommendations established by the law of procedures for the scientific use of animals, being approved for execution by the Animal Ethics and Research Committee of UFT under protocol number 23101.002359/2020-31. Every effort was made to avoid suffering or undue pain; the mice were monitored for weight loss and gain and clinical manifestations such as lethargy, hypothermia, and difficulty breathing. The animals were euthanized using ketamine (300 mg/kg) (Vetbrands®, Rio de Janeiro, Brazil) and xylazine hydrochloride (22.5 mg/kg) (Syntec®, Piracicaba, Brazil) [17 (link),18 (link),19 (link)].
Free full text: Click here
